Evidence map›Paper›PMID 39219724›Full record

ArticleWorld journal of stem cells2024

Mesenchymal stem cells: A promising therapeutic avenue for non-alcoholic fatty liver disease.

Chun-Han Cheng, Wen-Rui Hao, Tzu-Hurng Cheng

Abstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of stem cells, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. [Mesenchymal stem cell-derived exosomes: a new hope for metabolic-associated fatty liver disease].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026
    Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Chun-Han ChengDepartment of Medical Education, Linkou Chang Gung Memorial Hospital, Taoyuan 33305, Taiwan.
Wen-Rui HaoDivision of Cardiology, Department of Internal Medicine, Shuang Ho Hospital, Ministry of Health and Welfare, Taipei Medical University, New Taipei 23561, Taiwan.
Tzu-Hurng ChengDepartment of Biochemistry, School of Medicine, College of Medicine, China Medical University, Taichung 404328, Taiwan. thcheng@mail.cmu.edu.tw.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-alcoholic fatty liver disease (NAFLD) is a pressing global health concern that is associated with metabolic syndrome and obesity. On the basis of the insights provided by Jiang

Indexed as

Clinical trialsInflammationLiver fibrosisMesenchymal stem cellsNon-alcoholic fatty liver diseaseRegenerative medicineStem cell therapyTherapeutic potential

Identifiers

PMID39219724
PMCPMC11362857

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.